Video Guide
Catalyst Database
Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.
Ticker
Drug | Disease (links)
Stage (next event)
Catalyst Date
GILD
PDUFA
Lenacapavir
Prevention of HIV as pre-exposure prophylaxis (PrEP)
June 19, 2025
PURPOSE 1-5 trials. 6/20/24- Ph3 PURPOSE 1 met key efficacy endpoints. 9/12/24- Results of interim analysis from PURPOSE 2. Presented latest outcomes from PURPOSE 1 & 2 at ID Week '24. 2/18/25- NDA accepted under priority review with PDUFA date of June 19, 2025.
Approval decision
Meeting
Biomedical meeting
American Diabetes Association (ADA) Annual Meeting
Diabetes
June 20–23, 2025
ADA 2024 meeting dates: June 20–23, 2025. https://professional.diabetes.org/scientific-sessions
Meeting dates
NUVB
PDUFA
Taletrectinib (ROS1 inhibitor)
Advanced or metastatic ROS1+ non-small cell lung cancer
June 23, 2025
TRUST-I/II trials. 6/1/24- Data at ASCO '24 and share results for TRUST-II study by YE 2024. 9/14/24- Presented results at ESMO '24. 12/23/24- NDA accepted and granted priority review by FDA w/ PDUFA goal date of June 23, 2025. 1/6/25- Received NMPA approval in China.
Approval decision
AGEN
Phase 2
Botensilimab (AGEN1181) (anti-CLTA-4)
Pancreatic cancer and melanoma
H1 2025
Big Mover: ACTIVATE Pancreatic & melanoma Study: Completed Ph2 enrollment. Data from the pancreatic study and melanoma study in H2 2024. 11/12/24 - Advancing to Ph3. Additional data in H1 2025.
Additional data readout
Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20
